NextCure Q2 EPS $(0.55) Misses $(0.38) Estimate
Portfolio Pulse from Benzinga Newsdesk
NextCure (NASDAQ:NXTC) reported a Q2 EPS loss of $(0.55), missing the analyst consensus estimate of $(0.38) by 44.74%. This is an improvement from the $(0.64) loss per share in the same period last year.
August 01, 2024 | 8:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NextCure reported a Q2 EPS loss of $(0.55), missing the analyst consensus estimate of $(0.38) by 44.74%. Despite the miss, the loss is an improvement from $(0.64) per share last year.
The significant miss on EPS estimates is likely to negatively impact the stock price in the short term. However, the improvement from last year's loss may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100